These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Why valganciclovir should not be indicated for liver recipients and high-dose acyclovir should not be removed from international cytomegalovirus guidelines. Kalil AC; Florescu DF Transplantation; 2011 Jan; 91(1):e8-9; author reply e10. PubMed ID: 21441850 [No Abstract] [Full Text] [Related]
26. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Flechner SM; Avery RK; Fisher R; Mastroianni BA; Papajcik DA; O'Malley KJ; Goormastic M; Goldfarb DA; Modlin CS; Novick AC Transplantation; 1998 Dec; 66(12):1682-8. PubMed ID: 9884259 [TBL] [Abstract][Full Text] [Related]
27. Less renal allograft fibrosis with valganciclovir prophylaxis for cytomegalovirus compared to high-dose valacyclovir: a parallel group, open-label, randomized controlled trial. Reischig T; Kacer M; Hruba P; Hermanova H; Hes O; Lysak D; Kormunda S; Bouda M BMC Infect Dis; 2018 Nov; 18(1):573. PubMed ID: 30442095 [TBL] [Abstract][Full Text] [Related]
38. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. Balfour HH; Chace BA; Stapleton JT; Simmons RL; Fryd DS N Engl J Med; 1989 May; 320(21):1381-7. PubMed ID: 2541335 [TBL] [Abstract][Full Text] [Related]
39. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Hodson EM; Jones CA; Webster AC; Strippoli GF; Barclay PG; Kable K; Vimalachandra D; Craig JC Lancet; 2005 Jun 18-24; 365(9477):2105-15. PubMed ID: 15964447 [TBL] [Abstract][Full Text] [Related]